A phase I/II study of nivolumab plus 5-fluorouracil plus interferon-α2b for unresectable fibrolamellar hepatocellular carcinoma
Timeframe: 2021 – 2022 Goal: Assess the potential of the combination of nivolumab, fluorouracil, and interferon alpha-2b as a treatment option for unresectable disease Principal Investigators: Sunyoung Lee, MD and Ahmed Kaseb, MD, University of Texas M.D. Anderson Cancer Center This phase I/II trial studies the side effects and how well the combination of nivolumab, …